VA-ECMO患者的动脉高氧血症与死亡率
研究分析2013–2018年单中心179例VA-ECMO患者的10,615份动脉血气,按PaO2三分位分组。VA-ECMO期间中位PaO2为122 mmHg(Q1-Q3 111-158 mmHg),90天非存活者显著高于存活者(134 mmHg vs 114 mmHg,P<0.001)。PaO2三分位越高,各时间点死亡率越高;T3(>144 mmHg)较T1(<115 mmHg)和T2的90天生存率降低(Bonferroni校正P<0.001和P=0.002),多因素Cox回归显示T3与院内、90天、1年死亡率显著相关。作者认为VA-ECMO期间高氧血症可能与全因死亡率增加相关。
要点
- VA-ECMO期间中位PaO2为122 mmHg(Q1-Q3 111-158 mmHg),90天非存活者高于存活者(134 mmHg vs 114 mmHg,P<0.001)。
- PaO2三分位越高,VA-ECMO植入后各时间点死亡率越高;T1(中位PaO2<115 mmHg)死亡率最低,T3(中位PaO2>144 mmHg)最高。
- Bonferroni多重检验显示T3较T1的90天生存率降低(P<0.001),T3较T2亦降低(P=0.002)。
- 多因素Cox回归显示,与T2和T1相比,T3与院内、90天和1年死亡率在所有终点均显著相关。
- 作者认为VA-ECMO期间高氧血症可能与全因死亡率增加相关,并提示需特别关注VA-ECMO患者。
适用人群与场景
- 2013–2018年在本心脏外科三级中心接受VA-ECMO的患者179例。
- 共分析10,615份动脉血气,检测PaO2及其与院内、90天和1年死亡率的关系。
诊断标准与关键阈值
- 按VA-ECMO期间中位PaO2三分位分组:T1为<115 mmHg,T3为>144 mmHg。
研究设计与关键结果
- 单中心分析179例VA-ECMO患者10,615份动脉血气,按PaO2三分位分组,评估院内、90天和1年死亡率。
- VA-ECMO期间中位PaO2为122 mmHg(Q1-Q3 111-158 mmHg);90天非存活者中位PaO2为134 mmHg(Q1-Q3 114-175 mmHg),存活者为114 mmHg(Q1-Q3 109-136 mmHg),P<0.001。
- VA-ECMO植入后各时间点死亡率随PaO2三分位升高而增加;T1(中位PaO2<115 mmHg)死亡率最低,T3(中位PaO2>144 mmHg)死亡率最高。
- Bonferroni多重检验:T3较T1的90天生存率降低(P<0.001),T3较T2亦降低(P=0.002)。
- 多因素Cox回归显示,与T2和T1相比,T3与院内、90天和1年死亡率在所有终点均显著相关。
证据类型、等级与局限
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为VA-ECMO期间高氧血症可能与全因死亡率增加相关,并提示需特别关注VA-ECMO患者。
- 原文结果进一步记录了高氧血症在普通重症患者中的已知毒性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Background: Venoarterial extracorporeal membrane oxygenation (VA-ECMO) can easily lead to supranormal oxygenation. The impact of hyperoxygenation beyond the early VA-ECMO support phase is unexplored. We sought to investigate its association with short- and long-term mortality. Methods: A total of 10,615 arterial blood gases of 179 patients undergoing VA-ECMO between 2013 and 2018 in our cardiosurgical tertiary center were analyzed for partial pressure of oxygen (PaO2) and its association with in-hospital, 90-day, and 1-year mortality. Patients were stratified into terciles (T) based on PaO2. Results: The median systemic PaO2 during VA-ECMO was 122 mm Hg (Q1-Q3, 111-158 mm Hg) and was significantly higher in 90-day nonsurvivors versus survivors (134 mm Hg [Q1-Q3, 114-175 mm Hg] vs. 114 mm Hg [Q1-Q3, 109-136 mm Hg]; P < 0.001). The incidence of mortality increased at all time points tested after VA-ECMO implantation along with the increasing terciles of PaO2. The lowest mortality rates were noted for patients with median PaO2 values of <115 mm Hg (T1), whereas patients with median PaO2 values of >144 mm Hg (T3) had the highest mortality rates. Bonferroni multiple testing analysis found the T3 of PaO2 to be a predictor of decreased 90-day survival in comparison with T1 (P < 0.001) and T2 (P = 0.002). Multivariable Cox regression analyses for in-hospital, 90-day, and 1-year mortality showed a significant association of the T3 compared with the T2 and the T1 of PaO2 to mortality across all endpoints. Conclusion: Hyperoxygenation during VA-ECMO might be associated with increased all-cause mortality. The results of our study further document the known toxicity of hyperoxygenation in general critical care patients and mark the need to focus specifically on VA-ECMO patients.
参考来源
- Celińska-Spodar M, Załęska-Kocięcka M, Banaś S, et al. ARTERIAL HYPEROXIA AND MORTALITY IN PATIENTS UNDERGOING VENOARTERIAL EXTRACORPOREAL MEMBRANE OXYGENATION. Shock. 2022. PMID: 36703274. doi:10.1097/SHK.0000000000002038
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。